220 related articles for article (PubMed ID: 19341176)
1. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer.
Kosacka M; Jankowska R
Pol Arch Med Wewn; 2009; 119(1-2):33-7. PubMed ID: 19341176
[TBL] [Abstract][Full Text] [Related]
2. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
3. [The prognostic value of cytokeratin 19 expression in non-small cell lung cancer].
Kosacka M; Jankowska R
Pneumonol Alergol Pol; 2007; 75(4):317-23. PubMed ID: 18080980
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
[TBL] [Abstract][Full Text] [Related]
5. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments.
Buccheri G; Torchio P; Ferrigno D
Chest; 2003 Aug; 124(2):622-32. PubMed ID: 12907552
[TBL] [Abstract][Full Text] [Related]
6. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer.
Kashiwabara K; Nakamura H; Kiguchi T; Yagyu H; Kishi K; Wei BR; Yoneyama K; Matsuoka K
Clin Chim Acta; 1997 Oct; 266(2):149-55. PubMed ID: 9437543
[TBL] [Abstract][Full Text] [Related]
7. Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.
Sertić Milić H; Franjević A; Bubanović G; Marušić A; Nikolić I; Puljić I
Wien Klin Wochenschr; 2015 Jun; 127(11-12):465-71. PubMed ID: 25917364
[TBL] [Abstract][Full Text] [Related]
8. Optimal cut-off values for CYFRA 21-1 expression in NSCLC patients depend on the presence of benign pulmonary diseases.
Xu RH; Liao CZ; Luo Y; Xu WL; Li K; Chen JX; Huang YF; Chen YC; Zhu L; Yuan WB
Clin Chim Acta; 2015 Feb; 440():188-92. PubMed ID: 25304744
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
Chen F; Luo X; Zhang J; Lu Y; Luo R
Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.
Cho A; Hur J; Hong YJ; Lee HJ; Kim YJ; Hong SR; Suh YJ; Im DJ; Kim YJ; Lee JS; Shim HS; Choi BW
Tumour Biol; 2016 Mar; 37(3):3205-13. PubMed ID: 26432331
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of serum tumor markers found in non-small cell lung cancer.
Hu Q; Xiao P; Li J; Yu P
J Cancer Res Ther; 2016; 12(1):117-20. PubMed ID: 27072222
[TBL] [Abstract][Full Text] [Related]
12. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
13. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.
Edelman MJ; Hodgson L; Rosenblatt PY; Christenson RH; Vokes EE; Wang X; Kratzke R
J Thorac Oncol; 2012 Apr; 7(4):649-54. PubMed ID: 22425913
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer.
Alm El-Din MA; Farouk G; Nagy H; Abd Elzaher A; Abo El-Magd GH
Int J Biol Markers; 2012 Jul; 27(2):e139-46. PubMed ID: 22467097
[TBL] [Abstract][Full Text] [Related]
15. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors.
Išić T; Savin S; Cvejić D; Marečko I; Tatić S; Havelka M; Paunović I
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1805-12. PubMed ID: 20204403
[TBL] [Abstract][Full Text] [Related]
16. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis.
Yu Z; Zhang G; Yang M; Zhang S; Zhao B; Shen G; Chai Y
Oncotarget; 2017 Jan; 8(3):4043-4050. PubMed ID: 28008142
[TBL] [Abstract][Full Text] [Related]
18. Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer.
Hur J; Lee HJ; Nam JE; Kim YJ; Hong YJ; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Lee HS; Choi BW
BMC Cancer; 2012 Sep; 12():392. PubMed ID: 22954172
[TBL] [Abstract][Full Text] [Related]
19. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum.
Patel JL; Erickson JA; Roberts WL; Grenache DG
Clin Biochem; 2010 Dec; 43(18):1449-52. PubMed ID: 20875814
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
Lung; 2001; 179(1):57-65. PubMed ID: 11479694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
